IRIS
TOSCANI, Denise
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.114
AS - Asia 2.966
EU - Europa 1.894
SA - Sud America 425
AF - Africa 223
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 1
Totale 8.631
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.014
SG - Singapore 1.002
CN - Cina 848
VN - Vietnam 504
IT - Italia 350
SE - Svezia 343
BR - Brasile 317
IE - Irlanda 311
HK - Hong Kong 213
DE - Germania 182
FI - Finlandia 170
ZA - Sudafrica 148
FR - Francia 138
TR - Turchia 114
NL - Olanda 83
AT - Austria 67
IN - India 65
CA - Canada 58
GB - Regno Unito 50
RU - Federazione Russa 48
AR - Argentina 42
BD - Bangladesh 36
MX - Messico 27
BE - Belgio 26
CZ - Repubblica Ceca 25
CI - Costa d'Avorio 23
IQ - Iraq 21
JP - Giappone 21
RO - Romania 19
KR - Corea 18
ES - Italia 17
PL - Polonia 17
CO - Colombia 14
PK - Pakistan 14
UA - Ucraina 14
VE - Venezuela 14
TH - Thailandia 13
EC - Ecuador 12
ID - Indonesia 11
PH - Filippine 11
CL - Cile 9
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 8
KE - Kenya 8
LT - Lituania 8
TN - Tunisia 8
MA - Marocco 7
PY - Paraguay 7
EG - Egitto 6
EU - Europa 6
IL - Israele 6
KZ - Kazakistan 6
TW - Taiwan 6
AL - Albania 4
BG - Bulgaria 4
BO - Bolivia 4
IR - Iran 4
MY - Malesia 4
SA - Arabia Saudita 4
SN - Senegal 4
AZ - Azerbaigian 3
BW - Botswana 3
CR - Costa Rica 3
DZ - Algeria 3
ET - Etiopia 3
JM - Giamaica 3
JO - Giordania 3
KW - Kuwait 3
OM - Oman 3
PE - Perù 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
AM - Armenia 2
BY - Bielorussia 2
CH - Svizzera 2
DK - Danimarca 2
EE - Estonia 2
HN - Honduras 2
HU - Ungheria 2
MD - Moldavia 2
MU - Mauritius 2
PT - Portogallo 2
QA - Qatar 2
SC - Seychelles 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
BH - Bahrain 1
BJ - Benin 1
BN - Brunei Darussalam 1
BZ - Belize 1
CG - Congo 1
CM - Camerun 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GD - Grenada 1
KH - Cambogia 1
KI - Kiribati 1
LB - Libano 1
LV - Lettonia 1
Totale 8.619
Salva come PNG Salva come JPEG
Città #
Singapore 488
Ashburn 441
Chandler 310
Dublin 309
San Jose 275
Dallas 242
Santa Clara 218
Beijing 216
Hong Kong 205
Ho Chi Minh City 162
Johannesburg 141
Parma 141
Hanoi 118
Ann Arbor 108
Boardman 103
Izmir 90
New York 90
Shanghai 90
Los Angeles 84
Dearborn 74
Munich 71
Lauterbourg 68
Nanjing 64
Vienna 62
Princeton 56
Hefei 39
Shenyang 38
Buffalo 36
Marseille 35
São Paulo 31
Helsinki 29
Jacksonville 27
Brussels 26
Columbus 26
Toronto 26
Wilmington 26
Council Bluffs 25
Düsseldorf 25
Da Nang 24
Kunming 24
Moscow 24
Abidjan 23
Hebei 23
Milan 23
Haiphong 20
Nanchang 20
Turku 20
Jinan 18
San Mateo 17
Tokyo 17
Brno 16
Jiaxing 16
Orem 16
The Dalles 16
Tianjin 16
Warsaw 15
Bologna 14
Bremen 14
Seattle 14
Atlanta 13
Montreal 13
Norwalk 13
Brooklyn 12
Chicago 12
Frankfurt am Main 12
London 12
Stockholm 12
Houston 11
Seoul 11
Biên Hòa 10
Denver 10
Kocaeli 10
Redmond 10
Rome 10
Woodbridge 10
Changsha 9
Chennai 9
Focsani 9
Jakarta 9
Ankara 8
Belo Horizonte 8
Poplar 8
San Francisco 8
Tashkent 8
Zhengzhou 8
Amsterdam 7
Baghdad 7
Can Tho 7
Guangzhou 7
Hải Dương 7
Mexico City 7
Ottawa 7
Pune 7
Rio de Janeiro 7
Salvador 7
Des Moines 6
Guayaquil 6
Modena 6
Nairobi 6
Philadelphia 6
Totale 5.370
Salva come PNG Salva come JPEG
Nome #
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 212
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 210
(2S,4R)-4-fluoroglutamine is converted into (2S,4R)-4-fluoroglutamate by glutaminase activity and may be exploited as a PET tracer in glutamine-addicted cancers 205
[18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma 198
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 195
The Proteasome and Myeloma-Associated Bone Disease 189
Novel targets for the treatment of relapsing multiple myeloma 189
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 187
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 178
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 178
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 172
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 172
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 166
ADENOSINE IN THE MYELOMA BONE MARROW NICHE: IMMUNE CHECKPOINT AND KEY PLAYER IN DISEASE PROGRESSION 165
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 161
Bortezomib improves bone integrity in multiple myeloma patients by blocking osteocyte death and autophagy 156
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 156
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 156
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 155
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 152
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients 151
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 151
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 150
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 147
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 147
Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma. 144
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 144
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors 140
The osteoblastic niche in the context of multiple myeloma 138
The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38 138
The impact of CD56 expression in smoldering myeloma patients on early progression 134
Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells 134
Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2 133
Possible targets to treat myeloma-related osteoclastogenesis 131
Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives 127
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 126
Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis 124
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 124
Gfi1 Transcription Factor Is a Pro-Survival Molecule in Multiple Myeloma Cells 121
CK2 Kinase Inhibitors Display Anti-Myeloma Effects and Antagonize Osteoclast Activity in Models of Multiple Myeloma Bone Marrow Microenvironment 118
Hypoxia-inducible factor (HIF)-1 is a therapeutic target in myeloma-induced angiogenesis and bone destruction in vitro and in vivo 115
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 113
Proteasome Inhibitors Block Myeloma-Induced Osteocyte Death in Vitro and in Vivo in Multiple Myeloma Patients 113
Relationship between bone imaging features and bone marrow cytokine and chemokine profiles in patients with monoclonal gammopathy 112
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 109
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 107
Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo 105
Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis 105
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 101
High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease 99
The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma 96
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction 95
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 95
Interleukin-3 induces activin A in bone marrow monocytes: role in multiple myeloma patients 94
The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease 93
Proteasome inhibitors modulate osteocyte death and autophagy in multiple myeloma 92
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules 90
NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model 90
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 89
Myeloma-Induced osteocyte death was blunted by proteasome inhibitors through the modulation of autophagy 88
The role of proteasome inhibitors in multiple myeloma bone disease and bone metastasis: Effects on osteoblasts and osteocytes 88
Pygo2 Is Overexpressed in Myeloma Cells With 1q21 Amplification Being Involved in Carfilzomib Resistance 84
Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: Impact on myeloma-induced alterations of bone remodeling 80
New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in pediatric orthopaedics 79
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+ 76
Role of osteocytes in myeloma bone disease: Anti-sclerostin antibody as new therapeutic strategy 65
A metabolic trade-off between malignant plasma cells and mesenchymal stromal cells sustains multiple myeloma growth 23
Totale 8.770
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.058
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.058
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202162 0 0 0 0 0 0 0 0 0 25 12 25
2021/2022284 6 5 9 27 9 6 41 32 13 16 23 97
2022/20231.282 144 139 92 99 101 140 41 80 372 30 31 13
2023/2024556 26 37 12 14 36 185 51 22 14 35 27 97
2024/20251.663 34 75 89 154 176 171 107 75 197 128 158 299
2025/20263.639 328 307 521 379 531 217 375 178 473 330 0 0
Totale 8.770